View All Publications
Mapping of vascular ZIP codes by phage display.
Teesalu T, Sugahara KN, Ruoslahti E
Methods Enzymol. 2012;503:35-56
A high-throughput label-free nanoparticle analyser.
Fraikin JL, Teesalu T, McKenney CM, Ruoslahti E, Cleland AN
Nat Nanotechnol. 2011 May;6(5):308-13
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Greenwald DR, Ruoslahti E
Science. 2010 May 21;328(5981):1031-5
Tissue-penetrating delivery of compounds and nanoparticles into tumors.
Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Girard OM, Hanahan D, Mattrey RF, Ruoslahti E
Cancer Cell. 2009 Dec 8;16(6):510-20
C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration.
Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16157-62
Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system.
Teesalu T, Kulla A, Simisker A, Sirén V, Lawrence DA, Asser T, Vaheri A
Thromb Haemost. 2004 Aug;92(2):358-68
Embryo implantation in mouse: fetomaternal coordination in the pattern of expression of uPA, uPAR, PAI-1 and alpha 2MR/LRP genes.
Teesalu T, Blasi F, Talarico D
Mech Dev. 1996 May;56(1-2):103-16
Tambet Teesalu's Research Focus
Dr. Teesalu uses phage display screens to identify homing peptides that bind to specific targets in the vasculature. Corresponding synthetic peptides are explored for targeting drugs, biological, and nanoparticles into tumors to increase their therapeutic
index. His scope includes understanding the molecular interactions involved to drive specificity and activity, focusing on Tumor Penetrating Peptides (TPP) that trigger bulk extravascular transport in the tumor tissue.
About Tambet Teesalu
Dr. Teesalu received his PhD at University of Helsinki, Faculty of Medicine (jointly at San Raffaele Biomedical Institute in Milan, Italy) in 1999 studying the molecular mechanisms of mouse embryo implantation. He trained as a postdoctoral scientist with Antti Vaheri at the University of Helsinki, Finald until 2001. From 2001 to 2005, Dr. Teesalu was CEO of Applied Phenomics LLC, Tartu, Estonia. In 2005 he joined Dr. Ruoslahti's lab at Sanford-Burnham Medical Research Institute as a postdoctoral scientist and became a staff scientist. Dr. Teesalu is now an Adjunct Assistant Professor here and a Visiting Professor, Head of Laboratory of Cancer Biology at the University of Tartu, Estonia.
Visiting Professor, University of Tartu, Faculty of Medicine